Pfizer's is selling its global infusion therapy business, Hospira Infusion Systems (HIS), to ICU Medical, in a cash/stock deal worth $1 billion.
The Hospira Infusion Systems business includes IV pumps, solutions, and devices that, when combined with ICU Medical's existing businesses, will create a leading infusion business, with estimated pro forma combined revenues of around $1.45 billion.
Under the terms of the deal, Pfizer will receive approximately $400 million in newly issued shares of ICU Medical common stock, giving it ownership in the firm of around 16.6 percent, as well as $600 million in cash.
source"http://www.pharmatimes.com/news/pfizer_sells_off_global_infusion_unit_to_icu_for_$1_billion_1155540
The Hospira Infusion Systems business includes IV pumps, solutions, and devices that, when combined with ICU Medical's existing businesses, will create a leading infusion business, with estimated pro forma combined revenues of around $1.45 billion.
Under the terms of the deal, Pfizer will receive approximately $400 million in newly issued shares of ICU Medical common stock, giving it ownership in the firm of around 16.6 percent, as well as $600 million in cash.
source"http://www.pharmatimes.com/news/pfizer_sells_off_global_infusion_unit_to_icu_for_$1_billion_1155540
Posts
